|Day Low/High||50.51 / 51.90|
|52 Wk Low/High||49.96 / 70.05|
Get ahead of the naysayers, says Jim Cramer. FANG and other tech leaders have gone cold, but they're not dead yet.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York.
President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated a type II variation application for the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for treatment in adult patients with first-line...
Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, expanded their...
KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.
U.S. stock futures suggest Wall Street will open with modest gains on Thursday; Facebook posts a blowout quarter; Amazon and Microsoft to report earnings; Ford is no longer a car company.
Rising oil prices, surging bond yields and mixed earnings forecasts have stalled overnight gains for global stocks and pulled U.S. equity futures into the red ahead of another hectic slate of corporate reports.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2018 which were highlighted by strong sales for Opdivo , Eliquis , and Orencia, important regulatory progress in Immuno-Oncology and strategic business...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved an every four-week (Q4W) Opdivo (nivolumab) monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced...
Let's look at the charts this afternoon.
Jim Cramer highlights Wendy's, Spirit AeroSystems, Dunkin Brands, Bristol-Meyers Squibb, Take-Two Interactive and more.
Jim Cramer says it was utter insanity. In earnings, these executives said exactly the wrong things.
Stocks rise Monday as concerns over prolonged military action in Syria fade and the focus for investors shifts to a heavy upcoming slate of U.S. corporate earnings.
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!
The drugmakers on April 16 released data from their respective studies at the Association for Cancer Research's annual meeting in Chicago.
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
Let's puzzle over Syria and the possibility of another 'Saturday Night Massacre.'
If President Trump is too busy to post anti-Amazon tweets, that's good news for the online retailer.
Why you can't blame the president for Wednesday's weakness.
But If you want to know what I think could work the loudest here? How about Amazon?
The fatality that came at the hands of a self-driving Uber vehicle was tragic. But keep in mind, self-driving cars will be safer than human drivers in the not-too-distant future.
Bristol-Myers Squibb Company (NYSE: BMY) will hold an investor event on Monday, April 16, 2018 at 6:00 p.
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...
For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.
Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY) and certain of its officers.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.